Comparison of cerebrovascular events between patients with MMD and AS-MMV
| Before PSM | After PSM | |||||||
| All cases (n=1173) | MMD (n=881) | AS-MMV (n=292) | HR p value | All cases (n=572) | MMD (n=286) | AS-MMV (n=286) | HR p value | |
| Cerebrovascular events during overall follow-up | ||||||||
| All events | 142 (12.1%) | 121 (13.7%) | 21 (7.2%) | 0.008 | 67 (11.7%) | 46 (16.1%) | 21 (7.3%) | 0.002 |
| Ischaemic stroke | 115 (9.8%) | 98 (11.1%) | 17 (5.8%) | 0.018 | 55 (9.6%) | 37 (12.9%) | 18 (6.3%) | 0.010 |
| Haemorrhage | 27 (2.3%) | 23 (2.6%) | 4 (1.4%) | 0.256 | 12 (2.1%) | 9 (3.1%) | 3 (1.0%) | 0.142 |
| Cerebrovascular events in the first 2 years | ||||||||
| All events | 105 (9.0%) | 91 (10.3%) | 14 (4.8%) | <0.001 | 48 (8.4%) | 34 (11.9%) | 14 (4.9%) | 0.003 |
| Ischaemic stroke | 85 (7.2%) | 75 (8.5%) | 10 (3.4%) | <0.001 | 38 (6.6%) | 27 (9.4%) | 11 (3.8%) | 0.001 |
| Haemorrhage | 20 (1.7%) | 16 (1.8%) | 4 (1.4%) | 0.606 | 10 (1.7%) | 7 (2.4%) | 3 (1.0%) | 0.333 |
AS-MMV, atherosclerosis-associated moyamoya vasculopathy; MMD, moyamoya disease; PSM, propensity score matching.